EUVIMEDEUVIMED entdecken
Crossref

Fumarate hydratase–deficient renal cell carcinoma: an oncology care institutional experience

Meenakshi Kamboj iD, Gurudutt Gupta, Sunil Pasricha, Anurag Mehta, Sudhir Rawal, Amitabh Singh, Anila Sharma, Garima Durga, Divya Bansal, Himanshi Diwan

APMIS · 2024

DOI: 10.1111/apm.13425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift APMIS, 2024. Verfasst von Meenakshi Kamboj und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Fumarate Hydratase, Kidney Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Renal cell carcinoma (RCC) accounts for 2% of all cancer cases worldwide, and majority are sporadic. The latest World Health Organization (WHO) classification of renal cell tumors (fifth edition, 2022) has molecularly defined renal tumor entities, which includes fumarate hydratase (FH)–deficient RCC. FH‐deficient RCC is an aggressive carcinoma caused by pathogenic alterations in FH gene, seen in 15% of patients with hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC) syndrome. These tumors occur more frequently at a younger age and present at an advanced stage, carrying a dismal prognosis. We report a series of 10 cases of FH‐deficient RCC. The mean age was 49.8 years, and all cases presented in advanced stages (III and IV). Morphologically, the cases had varied architectural patterns with characteristic eosinophilic macronucleoli and perinucleolar halo. On immunohistochemistry (IHC), all showed diffuse nucleo‐cytoplasmic expression of S‐(2‐succino)‐cysteine (2‐SC), with loss of FH in seven cases. FH‐deficient RCCs are aggressive neoplasms and can be diagnosed using specific IHC markers (FH and 2‐SC). These patients should undergo germline testing for FH gene mutation, genetic counseling, and surveillance of family members.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Renal CellFumarate HydrataseKidney NeoplasmsHumansMiddle AgedFemaleMaleAdultImmunohistochemistryAgedNeoplastic Syndromes, HereditaryGerm-Line MutationBiomarkers, TumorCysteineSkin NeoplasmsUterine NeoplasmsLeiomyomatosis

Stichwörter der Autor:innen

Fumarate hydrataseS‐(2‐succino)‐cysteinegermlinehereditary leiomyomatosis and renal cell cancer syndromerenal cell carcinoma

Substanzen

Fumarate HydrataseS-(2-succinyl)cysteineBiomarkers, TumorCysteine

Autor:innen und Institutionen

  • Department of Histopathology and Cytopathology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.
  • Laboratory Services & Molecular Diagnostics, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.
  • Department of GenitoUro-Oncology, Rajiv Gandhi Cancer Institute & Research Centre, Delhi, India.

ORCID-Profile: Meenakshi Kamboj

Zitieren

APA

Kamboj, M., Gupta, G., Pasricha, S., Mehta, A., Rawal, S., Singh, A., Sharma, A., Durga, G., Bansal, D., & Diwan, H. (2024). Fumarate hydratase–deficient renal cell carcinoma: an oncology care institutional experience. APMIS. https://doi.org/10.1111/apm.13425

Vancouver

Kamboj M, Gupta G, Pasricha S, Mehta A, Rawal S, Singh A, et al. Fumarate hydratase–deficient renal cell carcinoma: an oncology care institutional experience. APMIS. 2024. doi:10.1111/apm.13425

BibTeX
@article{Kamboj2024,
  author = {Kamboj, Meenakshi and Gupta, Gurudutt and Pasricha, Sunil and Mehta, Anurag and Rawal, Sudhir and Singh, Amitabh and Sharma, Anila and Durga, Garima and Bansal, Divya and Diwan, Himanshi},
  title = {Fumarate hydratase–deficient renal cell carcinoma: an oncology care institutional experience},
  journal = {APMIS},
  year = {2024},
  doi = {10.1111/apm.13425}
}
Kostenlos starten →